They range from reduced glycolysis in APOE4-expressing cells (Wu et al., 2018; Fang et al., 2021; Zhang et al., 2023), via a metabolic shift from oxidative phosphorylation to glycolysis in APOE4 or AD patient cells (Sonntag et al., 2017; Williams et al., 2020; Farmer et al., 2021; Lee et al., 2023) to an increase in oxidative phosphorylation in APOE4 induced neurons (Budny et al., 2024). This evidence concerns the gene APOE and Alzheimer disease.